Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

An innovative and collaborative partnership between patients with rare disease and industry-supported registries: the Global aHUS Registry.

Woodward L, Johnson S, Walle JV, Beck J, Gasteyger C, Licht C, Ariceta G; aHUS Registry SAB.

Orphanet J Rare Dis. 2016 Nov 21;11(1):154. Review.

2.

The global aHUS registry: methodology and initial patient characteristics.

Licht C, Ardissino G, Ariceta G, Cohen D, Cole JA, Gasteyger C, Greenbaum LA, Johnson S, Ogawa M, Schaefer F, Vande Walle J, Frémeaux-Bacchi V.

BMC Nephrol. 2015 Dec 10;16:207. doi: 10.1186/s12882-015-0195-1.

3.

The NCI All Ireland Cancer Conference.

Johnston PG, Daly PA, Liu E.

Oncologist. 1999;4(4):275-277.

4.

Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.

Mallett A, Hughes P, Szer J, Tuckfield A, Van Eps C, Cambell SB, Hawley C, Burke J, Kausman J, Hewitt I, Parnham A, Ford S, Isbel N.

Intern Med J. 2015 Oct;45(10):1054-65. doi: 10.1111/imj.12864.

PMID:
26247170
5.

Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome.

Lapeyraque AL, Frémeaux-Bacchi V, Robitaille P.

Pediatr Nephrol. 2011 Apr;26(4):621-4. doi: 10.1007/s00467-010-1719-3. Epub 2010 Dec 15.

PMID:
21161283
6.

Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.

Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provôt F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM.

Am J Kidney Dis. 2016 Jul;68(1):84-93. doi: 10.1053/j.ajkd.2015.12.034. Epub 2016 Mar 21.

7.

Suspected atypical haemolytic uraemic syndrome in two post-partum patients with foetal-death in utero responding to eculizumab.

Chua J, Paizis K, He SZ, Mount P.

Nephrology (Carlton). 2017 Feb;22 Suppl 1:18-22. doi: 10.1111/nep.12935. Review.

PMID:
28176472
8.

Clinical guides for atypical hemolytic uremic syndrome in Japan.

Kato H, Nangaku M, Hataya H, Sawai T, Ashida A, Fujimaru R, Hidaka Y, Kaname S, Maruyama S, Yasuda T, Yoshida Y, Ito S, Hattori M, Miyakawa Y, Fujimura Y, Okada H, Kagami S; Joint Committee for the Revision of Clinical Guides of Atypical Hemolytic Uremic Syndrome in Japan.

Pediatr Int. 2016 Jul;58(7):549-55. doi: 10.1111/ped.13044.

PMID:
27460397
9.

Long-term remission with eculizumab in atypical haemolytic uraemic syndrome.

Carter S, Hewitt I, Kausman J.

Nephrology (Carlton). 2017 Feb;22 Suppl 1:7-10. doi: 10.1111/nep.12932. Review.

PMID:
28176479
10.

An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.

Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S.

Nefrologia. 2015;35(5):421-47. doi: 10.1016/j.nefro.2015.07.005. Epub 2015 Oct 9. English, Spanish.

11.

Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.

Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V; French Study Group for aHUS/C3G.

Nat Rev Nephrol. 2012 Nov;8(11):643-57. doi: 10.1038/nrneph.2012.214. Epub 2012 Oct 2. Review.

PMID:
23026949
12.

Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey.

Gediz F, Payzin BK, Ecemis S, Güler N, Yilmaz AF, Topcugil F, Berdeli A.

Transfus Apher Sci. 2016 Dec;55(3):357-362. doi: 10.1016/j.transci.2016.09.017. Epub 2016 Sep 30.

PMID:
27742267
13.

Liver transplantation for aHUS: still needed in the eculizumab era?

Coppo R, Bonaudo R, Peruzzi RL, Amore A, Brunati A, Romagnoli R, Salizzoni M, Galbusera M, Gotti E, Daina E, Noris M, Remuzzi G.

Pediatr Nephrol. 2016 May;31(5):759-68. doi: 10.1007/s00467-015-3278-0. Epub 2015 Nov 24.

14.

Eculizumab: a review of its use in atypical haemolytic uraemic syndrome.

Keating GM.

Drugs. 2013 Dec;73(18):2053-66. doi: 10.1007/s40265-013-0147-7. Review.

PMID:
24249647
15.

Life-threatening pregnancy-associated atypical haemolytic uraemic syndrome and its response to eculizumab.

Gately R, San A, Kurtkoti J, Parnham A.

Nephrology (Carlton). 2017 Feb;22 Suppl 1:32-35. doi: 10.1111/nep.12938. Review.

PMID:
28176475
16.

Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment.

Walle JV, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H.

J Nephrol. 2017 Feb;30(1):127-134. doi: 10.1007/s40620-016-0288-3. Epub 2016 Mar 19.

17.

Irreversible severe kidney injury and anuria in a 3-month-old girl with atypical haemolytic uraemic syndrome under administration of eculizumab.

Okuda Y, Ishikura K, Terano C, Harada R, Hamada R, Hataya H, Ogata K, Honda M.

Nephrology (Carlton). 2016 Mar;21(3):261-5. doi: 10.1111/nep.12582.

PMID:
26818219
18.

Atypical hemolytic uremic syndrome recurrence after kidney transplantation.

Matar D, Naqvi F, Racusen LC, Carter-Monroe N, Montgomery RA, Alachkar N.

Transplantation. 2014 Dec 15;98(11):1205-12. doi: 10.1097/TP.0000000000000200.

PMID:
24933457
19.

Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature.

Manenti L, Gnappi E, Vaglio A, Allegri L, Noris M, Bresin E, Pilato FP, Valoti E, Pasquali S, Buzio C.

Nephrol Dial Transplant. 2013 Sep;28(9):2246-59. doi: 10.1093/ndt/gft220. Epub 2013 Jun 19. Review.

PMID:
23787552
20.

Success of eculizumab in the treatment of atypical hemolytic uremic syndrome.

Baskin E, Gulleroglu K, Kantar A, Bayrakci U, Ozkaya O.

Pediatr Nephrol. 2015 May;30(5):783-9. doi: 10.1007/s00467-014-3003-4. Epub 2014 Nov 11.

PMID:
25384530

Supplemental Content

Support Center